01—Abstract
Summary
Summary of the 10-Q filed August 6, 2024. Cited figures are marked; the original filing is the authoritative source.
Zoetis Inc. (ZTS) reported strong top-line growth for the second quarter and first half of 2024, with total revenue increasing by 8%a and 9% respectively, driven by a combination of price increases and volume growth in key product categories like dermatology and new products.
Operationally, revenue growth was even more robust, up 11%b for the quarter and 12% for the half-year, indicating underlying business strength despite unfavorable foreign exchange impacts. Profitability saw a decline in reported net income for the quarter, primarily due to higher restructuring and divestiture-related costs and other (income)/deductions—net, which included a significant loss on assets held for sale. However, excluding these items, adjusted net income and adjusted diluted EPS showed healthy year-over-year increases, demonstrating continued operational efficiency and profitability.
02—Key points
Key Highlights
- Total revenue increased by 8% to $2,361 million for the three months ended June 30, 2024, and by 9% to $4,551 million for the six months ended June 30, 2024.
- Operational revenue growth, excluding foreign exchange, was strong at 11% for the quarter and 12% for the half-year, driven by price increases and new product volumes.
- U.S. segment revenue saw robust growth of 12% for the quarter and 14% for the half-year, primarily driven by companion animal products.
- International segment revenue grew 4% for the quarter and 3% for the half-year, with operational growth at 10% and 9% respectively, despite significant foreign exchange headwinds.
- The company is actively managing its portfolio, planning to divest its medicated feed additive product portfolio and related assets for $350 million.
- Research and development expenses increased by 17% for the quarter and 16% for the half-year, reflecting continued investment in innovation.
- Despite a reported decrease in net income attributable to Zoetis Inc. for the quarter, adjusted net income and adjusted diluted EPS increased by 9% and 11% respectively for the quarter, showcasing underlying profitability improvements.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2024filed August 6, 2024Financial Statements
Q2 FY2024 against Q2 FY2023
| Line item | Q2 FY2024Q2 FY2023 | Change |
|---|---|---|
| Revenue | $2.36B$2.18B | +8.3% |
| Cost of Revenue | $668.00M$607.00M | +10.0% |
| Gross Profit | $1.69B$1.57B | +7.6% |
| SG&A Expenses | $581.00M$556.00M | +4.5% |
| Interest Expense | $59.00M$58.00M | +1.7% |
| Net Income | $624.00M$670.00M | −6.9% |
| EPS (Basic) | $1.37$1.45 | −5.5% |
| EPS (Diluted) | $1.37$1.45 | −5.5% |
| Shares Outstanding (Basic) | 455.50M461.90M | −1.4% |
| Shares Outstanding (Diluted) | 456.00M462.90M | −1.5% |
05—Questions
Frequently Asked Questions
What was the primary driver of revenue growth in the current period?
Revenue growth was primarily driven by a combination of price increases (approximately 8% for the quarter and 7% for the half-year) and volume growth from new products and key dermatology products. Operational revenue growth, which excludes the impact of foreign exchange, was particularly strong, indicating healthy underlying business performance.
Why did net income attributable to Zoetis Inc. decrease for the quarter, despite revenue growth?
The reported decrease in net income for the quarter was influenced by several factors including higher restructuring charges and certain acquisition and divestiture-related costs, a significant loss on assets held for sale related to the planned divestiture of the medicated feed additive portfolio, and other (income)/deductions—net. When excluding these items, adjusted net income and adjusted diluted EPS showed positive growth.
How is Zoetis managing its product portfolio and what is the impact of the planned divestiture?
Zoetis is actively managing its portfolio, as evidenced by the planned divestiture of its medicated feed additive product portfolio and related assets for $350 million. This strategic move allows the company to focus on higher-growth areas and potentially reinvest in core strategic priorities. The assets and liabilities related to this divestiture have been classified as held for sale.
What is the company's outlook on liquidity and capital resources?
Zoetis believes its cash on hand, operating cash flows, and existing financing arrangements are sufficient to meet its liquidity needs for the next twelve months and beyond. The company has a $1.0 billion revolving credit facility and had no amounts drawn as of June 30, 2024, indicating a strong liquidity position.
06—Continue